735 related articles for article (PubMed ID: 26941338)
21. Experience with a third-generation implantable cardioverter-defibrillator.
Saksena S; Mehta D; Krol RB; Tullo NG; Saxena A; Kaushik R; Neglia J
Am J Cardiol; 1991 Jun; 67(16):1375-84. PubMed ID: 2042568
[TBL] [Abstract][Full Text] [Related]
22. Complications of permanent cardiac pacing in patients with persistent left superior vena cava.
Polewczyk A; Kutarski A; Czekajska-Chehab E; Adamczyk P; Boczar K; Polewczyk M; Janion M
Cardiol J; 2014; 21(2):128-37. PubMed ID: 24526508
[TBL] [Abstract][Full Text] [Related]
23. Reduction of ICD shock burden by eliminating back-up pacing induced ventricular tachyarrhythmias.
Theis C; Mollnau H; Sonnenschein S; Konrad T; Himmrich E; Bock K; Schulz E; Kämpfner D; Gerhardt S; Quesada Ocete B; Münzel T; Rostock T
J Cardiovasc Electrophysiol; 2014 Aug; 25(8):889-895. PubMed ID: 24654876
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous subcutaneous implantable cardioverter-defibrillator and leadless pacemaker implantation for patients at high risk of infection: a retrospective case series report.
Calvagna GM; Valsecchi S
J Interv Card Electrophysiol; 2023 Nov; ():. PubMed ID: 37938506
[TBL] [Abstract][Full Text] [Related]
25. Combined use of non-thoracotomy cardioverter defibrillators and endocardial pacemakers.
Noguera HH; Peralta AO; John RM; Venditti FJ; Martin DT
Heart; 1997 Jul; 78(1):50-5. PubMed ID: 9290402
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of combined cardiac contractility modulation and subcutaneous defibrillator therapy in patients with heart failure and reduced ejection fraction.
Röger S; Rudic B; Akin I; Shchetynska-Marinova T; Fastenrath F; Tülümen E; Liebe V; El-Battrawy I; Baumann S; Kuschyk J; Borggrefe M
Clin Cardiol; 2018 Apr; 41(4):518-524. PubMed ID: 29697870
[TBL] [Abstract][Full Text] [Related]
27. [New Innovative Pacemaker Devices - Leadless Pacemaker, Subcutaneous ICD].
Napp A; Reith S
Dtsch Med Wochenschr; 2018 Nov; 143(22):1617-1622. PubMed ID: 30376685
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
Roses-Noguer F; Jarman JW; Clague JR; Till J
Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
[TBL] [Abstract][Full Text] [Related]
29. Should stimulation therapy for congestive heart failure be combined with defibrillation backup?
Gaita F; Bocchiardo M; Porciani MC; Vivalda L; Colella A; Di Donna P; Caponi D; Bruzzone M; Padeletti L
Am J Cardiol; 2000 Nov; 86(9A):165K-158K. PubMed ID: 11084118
[TBL] [Abstract][Full Text] [Related]
30. Predictors of successful defibrillation threshold test during CRT-D implantation.
Przybylski A; Oreziak A; Lewandowski Z; Hasiec A; Orczykowski M; Walczak F
Kardiol Pol; 2010 May; 68(5):512-8. PubMed ID: 20491010
[TBL] [Abstract][Full Text] [Related]
31. Transcutaneous T wave shock: a universal method for ventricular fibrillation induction.
Mazer CD; Greene MB; Misale PS; Newman D; Dorian P
Pacing Clin Electrophysiol; 1997 Dec; 20(12 Pt 1):2930-5. PubMed ID: 9455753
[TBL] [Abstract][Full Text] [Related]
32. Cardiac implantable electronic device and vascular access: Strategies to overcome problems.
Kusztal M; Nowak K
J Vasc Access; 2018 Nov; 19(6):521-527. PubMed ID: 29552930
[TBL] [Abstract][Full Text] [Related]
33. The effect of hyperkalaemia on cardiac rhythm devices.
Barold SS; Herweg B
Europace; 2014 Apr; 16(4):467-76. PubMed ID: 24465006
[TBL] [Abstract][Full Text] [Related]
34. Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management.
Kooiman KM; Knops RE; Olde Nordkamp L; Wilde AA; de Groot JR
Heart Rhythm; 2014 Mar; 11(3):426-34. PubMed ID: 24321235
[TBL] [Abstract][Full Text] [Related]
35. Feasibility and efficacy of percutaneously delivered leadless cardiac pacing in an in vivo ovine model.
Koruth JS; Rippy MK; Khairkhahan A; Ligon DA; Hubbard CA; St Goar F; Lee R; Ribeiro L; Miller M; Dukkipati S; Neuzil P; Reddy VY
J Cardiovasc Electrophysiol; 2015 Mar; 26(3):322-8. PubMed ID: 25367066
[TBL] [Abstract][Full Text] [Related]
36. A worldwide experience of the management of battery failures and chronic device retrieval of the Nanostim leadless pacemaker.
Lakkireddy D; Knops R; Atwater B; Neuzil P; Ip J; Gonzalez E; Friedman P; Defaye P; Exner D; Aonuma K; Doshi R; Sperzel J; Reddy V
Heart Rhythm; 2017 Dec; 14(12):1756-1763. PubMed ID: 28705736
[TBL] [Abstract][Full Text] [Related]
37. Nanostim leadless pacemaker retrieval and simultaneous micra leadless pacemaker replacement: a single-center experience.
Asirvatham RS; Vaidya VR; Thome TM; Friedman PA; Cha YM
J Interv Card Electrophysiol; 2020 Jan; 57(1):125-131. PubMed ID: 31728873
[TBL] [Abstract][Full Text] [Related]
38. The modular cardiac rhythm management system: the EMPOWER leadless pacemaker and the EMBLEM subcutaneous ICD.
Tjong FVY; Koop BE
Herzschrittmacherther Elektrophysiol; 2018 Dec; 29(4):355-361. PubMed ID: 30382341
[TBL] [Abstract][Full Text] [Related]
39. A Modular Communicative Leadless Pacing-Defibrillator System.
Knops RE; Lloyd MS; Roberts PR; Wright DJ; Boersma LVA; Doshi R; Friedman PA; Neuzil P; Blomström-Lundqvist C; Bongiorni MG; Burke MC; Gras D; Kutalek SP; Amin AK; Fu EY; Epstein LM; Tolosana JM; Callahan TD; Aasbo JD; Augostini R; Manyam H; Nair DG; Mondésert B; Su WW; Pepper C; Miller MA; Grammes J; Saleh K; Marquie C; Merchant FM; Cha YM; Cunnington C; Frankel DS; West J; Matznick E; Swackhamer B; Brisben AJ; Weinstock J; Stein KM; Reddy VY; Mont L;
N Engl J Med; 2024 May; ():. PubMed ID: 38767244
[TBL] [Abstract][Full Text] [Related]
40. Predictors of pacemaker dependence and pacemaker dependence as a predictor of mortality in patients with implantable cardioverter defibrillator.
Sood N; Crespo E; Friedman M; Guertin D; Zweibel S; Kluger J; Clyne CA
Pacing Clin Electrophysiol; 2013 Aug; 36(8):945-51. PubMed ID: 23668483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
